Physician profile
Brian D Glaser
NPI 1083672067
$9,537.00
in general payments reported to CMS, 2019-2025
58 companies · $1,360 in 2025
The $1,360 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,401 · 2020: $1,232 · 2021: $1,601 · 2022: $1,413 · 2023: $1,354 · 2024: $1,175 · 2025: $1,360.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,890.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,890.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,454.30 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $1,197.48 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $853.14 | 2020-2025 | |
| Amgen INC. | $759.84 | 2019-2025 | Repatha, Evenity, Otezla |
| Glaxosmithkline, LLC. | $759.45 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $615.32 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $457.00 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $434.34 | 2019-2024 | Jardiance, Emgality, Mounjaro |
| Corcept Therapeutics | $250.61 | 2024-2025 | Korlym |
| Takeda Pharmaceuticals U.S.A., INC. | $232.07 | 2019-2021 | |
| Esperion Therapeutics, INC. | $196.55 | 2020-2025 | Nexletol |
| Amarin Pharma, INC. | $185.32 | 2019-2022 | |
| Allergan, INC. | $178.65 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $156.88 | 2019-2025 | |
| Corium, LLC | $148.85 | 2022-2023 | Azstarys |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Glaser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.